Spagnolo P, et al. - In this post hoc analysis, researchers determined the impact of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF). Included patients were participants from 3 phase 3, double-blind, controlled trials of pirfenidone [CAPACITY; ASCEND, who were randomized to placebo (n = 624)]. These subjects were categorized by baseline metformin use for primary analysis. They also evaluated outcomes in patients with diabetes and/or hyperglycemia (impaired glucose tolerance [IGT] and diabetes population [IGT-diabetes population]) and all patients included in the 3 studies (intention-to-treat [ITT] population). Findings revealed no impact of metformin on clinically relevant outcomes [disease progression (forced vital capacity [FVC] decline ≥10%, 6-min walking distance [6MWD] decline ≥50 m, or death) in patients with IPF.